Cabaletta Bio, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended on December 31, 2024, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408(a) of Regulation S-K, except as described in the table below:
| Name and Title | Action | Action Date | Duration of Trading Arrangements(1) | Rule 10b5-1 Trading Arrangement?(Y/N)* | Aggregate Number of Securities Subject to Trading Arrangement |
|---|---|---|---|---|---|
| Steven Nichtberger Chief Executive Officer | Terminate(2) | October 18, 2024 | July 8, 2024 - July31, 2025 | Y | Up to 350,000 shares to be sold |
| Steven Nichtberger Chief Executive Officer | Adopt(2) | October 18, 2024 | February 16, 2025 – July 27, 2026 | Y | Up to 350,000 shares to be sold |
| Gwendolyn Binder President of Science and Technology | Terminate | November 21, 2024 | February 20, 2024 – February 21, 2025 | Y | Up to 100,756 shares to be sold |
| Gwendolyn Binder President of Science and Technology | Adopt | December 18, 2024 | March 27, 2025 to December 12, 2025 | Y | Up to 100,756 shares to be sold |
- Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).
(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.
(2) Represents the modification, as described in Rule 10b5-1(c)(1)(iv) under the Exchange Act, of a written trading arrangement adopted on November 9, 2023 that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.